(4-traders.com) Harvard Apparatus Regenerative Technology, or HART, recently reported that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the HART-Trachea, which is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. David Green, President and CEO of HART, said,...http://www.4-traders.com/HARVARD-APPARATUS-REGENER-12927362/news/Harvard-Apparatus-Regenerative-Tech--ology-Gets-Orphan-Drug-Designation-from-US-Food-and-Drug-Adm-19076168/
